Preferred Label : concizumab;
MeSH note : blocked the interaction between FXa and factor pathway inhibitor in a rabbit hemophilia
model;
MeSH hyponym : monoclonal antibody 2021;
Is substance : O;
UNII : 68603V9EAF;
Origin ID : C574488;
UMLS CUI : C3494079;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Record concept(s)
Semantic type(s)
UMLS correspondences (same concept)
https://www.ema.europa.eu/en/medicines/human/EPAR/alhemo
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
concizumab
concizumab
concizumab
drug approval
europe
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
risk management
product surveillance, postmarketing
hemorrhage
adolescent
adult
aged
hemophilia B
hemophilia A
injections, subcutaneous
Hereditary factor VIII deficiency disease with inhibitor (disorder)
Hereditary factor IX deficiency disease with inhibitor (disorder)
tissue factor pathway inhibitor
drug interactions
pregnancy
breast feeding
Female of Childbearing Potential
drug evaluation, preclinical
---
https://ansm.sante.fr/tableau-acces-derogatoire/concizumab
2024
false
false
false
France
French
concizumab
guidelines for drug use
summary of product characteristics
package leaflet
technical report
hemophilia A
hemophilia B
hemorrhage
adolescent
---
https://www.has-sante.fr/jcms/p_3563330/fr/alhemo-concizumab-hemophilie-a-et-b-avec-inhibiteurs
2024
false
false
false
France
Hereditary factor VIII deficiency disease with inhibitor (disorder)
hemophilia A
Hereditary factor IX deficiency disease with inhibitor (disorder)
evaluation of the transparency committee
concizumab
hemophilia B
---
https://www.has-sante.fr/jcms/p_3466237/fr/alhemo-concizumab-hemophilie-a-et-b-avec-inhibiteurs
2023
false
false
false
France
antibodies, monoclonal, humanized
treatment outcome
insurance, health, reimbursement
Hereditary factor VIII deficiency disease with inhibitor (disorder)
hemophilia A
hemorrhage
adolescent
adult
Hereditary factor IX deficiency disease with inhibitor (disorder)
concizumab
evaluation of the transparency committee
hemophilia B
concizumab
---
https://ansm.sante.fr/actualites/avis-de-lansm-du-05-09-2023-sur-le-medicament-alhemo-dans-le-cadre-dune-demande-daap
2023
false
false
false
France
French
drug information
concizumab
package leaflet
summary of product characteristics
---